Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News XenoPort XNPT

Healthcare Biotechnology
"XenoPort Inc is a biopharmaceutical company. It is engaged in developing and commercializing a portfolio of internally discovered product candidates for the treatment of neurological and other disorders."

Recent & Breaking News (NDAQ:XNPT)

XenoPort Issues Statement

Business Wire October 15, 2013

Clinton Group Calls on Xenoport to Hire a New CEO and Focus on Promising Drug in its Pipeline

PR Newswire October 15, 2013

WED Foundation and XenoPort Announce Launch of New "Patient Odyssey" Survey Assessing Day-to-Day Impact of RLS/WED on Both Patients and Loved Ones

Business Wire September 26, 2013

Five Star Equities Issues New Research Reports on CCXI, NSTG, TTM and XNPT

Accesswire September 11, 2013

XenoPort Announces Inclusion of HORIZANT (gabapentin enacarbil) in the WED Foundation Revised Consensus Statement on the Management of RLS/WED

Business Wire September 11, 2013

XenoPort Announces Preliminary Results of Phase 1 Studies Supporting Further Development of XP23829

Business Wire September 9, 2013

XenoPort to Present at the Morgan Stanley Global Healthcare Conference

Business Wire September 3, 2013

Jeryl L. Hilleman Joins Ocera Therapeutics as Chief Financial Officer

Globe Newswire September 3, 2013

XenoPort Reports Second Quarter Financial Results

Business Wire August 6, 2013

XenoPort Announces New Employment Inducement Awards

Business Wire August 2, 2013

XenoPort to Release Second Quarter Financial Results on August 6

Business Wire July 30, 2013

XenoPort Announces Inclusion of Horizant (Gabapentin Enacarbil) in Guidelines for Long-Term Treatment of Restless Legs Syndrome/Willis-Ekbom Disease

Business Wire July 23, 2013

XenoPort Announces New Employment Inducement Awards

Business Wire July 5, 2013

XenoPort to Present at the Wells Fargo Securities Healthcare Conference

Business Wire June 11, 2013

XenoPort Announces New Employment Inducement Awards

Business Wire June 7, 2013

Free Research Reports on HERO, IQNT, LDK and XNPT Issued by the Bedford Report

Marketwired May 21, 2013

XenoPort Reports Top-Line Results of Phase 3 Trial of Arbaclofen Placarbil for Spasticity in Multiple Sclerosis Patients

Business Wire May 20, 2013

XenoPort Provides Update on Availability of Horizant

Business Wire May 17, 2013

XenoPort Announces New Employment Inducement Awards

Business Wire May 3, 2013

XenoPort Reports First Quarter Financial Results

Business Wire April 24, 2013